Drug intelligence / Profile preview

AGB103

Development stage: Preclinical
Lead developer: ABL Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AGB103 is a CD19-targeted therapeutic candidate being developed by Agni Bio for the treatment of autoimmune diseases. It utilizes Agni Bio's proprietary Vβ17-directed T memory redirection platform, which is designed to selectively engage and redirect T memory cells to deplete CD19-positive B cells. This approach aims to address the underlying pathology of various autoimmune conditions by eliminating the B-cell populations responsible for autoantibody production and immune dysregulation. As of early 2026, the program is in the IND-enabling stage of development.

Targets

CD19 (B lymphocyte antigen CD19)T cell receptor beta variable 17

Beyond the preview

Go deeper on AGB103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGB103.

Explore the full profile